Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $41.44

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten brokerages that are currently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $41.44.

A number of equities analysts recently commented on ARWR shares. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. B. Riley reaffirmed a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Chardan Capital reaffirmed a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 40,322 shares of the business's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $10.07, for a total value of $406,042.54. Following the sale, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at approximately $40,502,093.85. The trade was a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 276,839 shares of company stock valued at $4,054,176. Corporate insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 25.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after buying an additional 2,222,223 shares during the last quarter. Norges Bank bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $38,622,000. Farallon Capital Management LLC purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $11,821,000. Two Sigma Investments LP increased its holdings in shares of Arrowhead Pharmaceuticals by 281.3% in the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock worth $14,934,000 after purchasing an additional 586,062 shares in the last quarter. Finally, Slate Path Capital LP raised its stake in shares of Arrowhead Pharmaceuticals by 7.1% in the fourth quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock worth $98,362,000 after purchasing an additional 347,000 shares during the last quarter. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Trading Up 5.3 %

Shares of ARWR stock traded up $0.65 during mid-day trading on Monday, reaching $13.01. The stock had a trading volume of 1,752,377 shares, compared to its average volume of 1,440,725. The firm has a market capitalization of $1.79 billion, a PE ratio of -2.52 and a beta of 0.99. The stock's 50-day moving average price is $14.99 and its two-hundred day moving average price is $18.50. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Equities analysts expect that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.